CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 150 enrolled
Drug / intervention
Urox +1 moredietary
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02396160
NCT02396160N/ACompleted

The Effect of Urox™(Crateva, Horsetail and Lindera Combination) in the Treatment of Overactive Bladder and Urinary Incontinence

The University of Queensland·interventional·Posted Mar 24, 2015·Updated May 5, 2016

In Brief

A clinical study evaluating Urox and Placebo for Overactive Bladder and 3 related conditions. Completed, enrolled 150 participants.

Detailed Summary

This study aims to assess the efficacy of a specialized herbal formula, Urox, versus control over 8 weeks, in a double blind, placebo controlled trial. 150 participants are being recruited, randomized and administered treatment or placebo for the period of 8 weeks after initial eligibility screening. Outcome measures include previously validated tools such as the 3 day symptom diary measuring self-recorded day frequency, nocturia, urgency and incontinence episodes. Quality of life improvements are being measured using the Incontinence Impact Questionnaire, Urinary Distress Inventory and the short version of the OverActive Bladder survey.

Study Details

Timeline

N/ACompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedMar 24, 2015
Enrollment StartAug 1, 2013
Primary CompletionDec 1, 2014
Study CompletionMay 1, 2015
TodayJul 2, 2026
Enrollment to primary: 1.3 yearsPosted 11.3 years ago

Interventions

Uroxdietary

Active treatment - Proprietary combination of Crateva nurvala, Equisetum arvense and Lindera aggregata herbs

Placeboother

Placebo - Identical vegetarian capsule containing color-matched cellulose to that of the active treatment